WO2006083916A2 - Novel adenosine a3 receptor modulators - Google Patents
Novel adenosine a3 receptor modulators Download PDFInfo
- Publication number
- WO2006083916A2 WO2006083916A2 PCT/US2006/003477 US2006003477W WO2006083916A2 WO 2006083916 A2 WO2006083916 A2 WO 2006083916A2 US 2006003477 W US2006003477 W US 2006003477W WO 2006083916 A2 WO2006083916 A2 WO 2006083916A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dione
- substituted
- purine
- alkyl
- imidazo
- Prior art date
Links
- 0 *C1=NN(*)c2nc(N(*)C(N(*)C3=O)=O)c3[n]2C1 Chemical compound *C1=NN(*)c2nc(N(*)C(N(*)C3=O)=O)c3[n]2C1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention pertains to new adenosine A3 receptor antagonists and methods of their use.
- Adenosine exerts a number of physiological functions through activation of four cell membrane receptors classified as A 1 , A 2A , A 2B and A 3 .
- the most recently discovered subtype, the A 3 subtype has been the subject of intensive pharmacological characterization. Although all adenosine subclasses belong to the G protein-coupled receptors they are associated with different second messenger systems.
- the A 3 subtype is believed to have a characteristic second messenger profile, in that it has been shown to mediate adenylyl cyclase inhibition and phospholipase C activation.
- the adenosine A 3 receptor is also believed to play a role in modulation of cerebral ischemia, inflammation, ischemic heart pre-conditioning and asthma.
- a 3 receptor agonists find use in the treatment of these diseases.
- the A 3 receptor is also a therapeutic target on cell growth, on apoptosis, on leukemic Jurkat T cells, on the human malignant melanoma A375 cell line and on human neutrophils.
- the human cloned A 3 adenosine receptor was first characterized with N 6 -(4-amino-3-[125I]iodobenzyl)adenosine.
- the compounds of this invention are potent and selective A 3 adenosine receptor modulators, e.g., adenosine receptor antagonists.
- Compounds of the invention include, inter alia, l-aralkyl-S-alkyl-lHj ⁇ H-pyrroloPjl- ⁇ purine ⁇ -diones, l-aralkyl-3- alkyl-lH,8H-imidazo[2,l-/lpurine-2,4-diones, and 8-aralkyl-6-alkyl-l,4-dihydro-8H- l,2,4a,6,8,9-hexaaza-fluorene-5,7-diones.
- X is CH or N
- R 1 and R 2 are each independently hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, or substituted aryl;
- R 3 is aryl, substituted aryl, alkyl, substituted alkyl, aralkyl, substituted aralkyl;
- R 4 is hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl, or substituted aryl; and one of the dashed lines represents a double bond and the other represents a single bond; or a pharmaceutically acceptable salt thereof.
- this invention provides compounds of the following Formula (II):
- R 5 and R 6 are each independently hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, or substituted aryl;
- R 7 is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, or substituted aralkyl;
- R 8 is alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl, or substituted aryl; or a pharmaceutically acceptable salt thereof.
- the compounds of this invention are useful in the treatment of cerebral ischemia, inflammation, neurodegeneration, glaucoma, ischemic heart pre-conditioning, cancer and asthma in mammals.
- the compounds of this invention are also useful as tools for the investigation of therapeutic targets on cell growth, on apoptosis, on leukemic Jurkat T cells, on human malignant melanoma A375 cell line and on human neutrophils. These compounds can also be used in screening assays to assess the activity of compounds in modulating the A 3 receptor.
- X is CH or N
- R 1 and R 2 are each independently hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, or substituted aryl;
- R 3 is aryl, substituted aryl, alkyl, substituted alkyl, aralkyl, substituted aralkyl;
- R 4 is hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl, or substituted aryl; or a pharmaceutically acceptable salt thereof.
- R 4 is hydrogen, alkyl or substituted alkyl, more preferably R 4 is hydrogen.
- R 3 is alkyl, more preferably methyl, substituted alkyl, aryl, more preferably phenyl, substituted aryl, preferably substituted phenyl, more preferably 4-substituted phenyl, still more preferably 4- fluorophenyl, or aralkyl.
- R 1 and R 2 are each independently hydrogen, alkyl, substituted alkyl, or aralkyl. More preferably, R 2 is alkyl, still more preferably propyl.
- the invention provides a compound represented by Formula (Ia):
- R 1 , R 2 , R 3 and R 4 are as described above; or a pharmaceutically acceptable salt thereof.
- R 4 is hydrogen, alkyl or substituted alkyl, more preferably R 4 is hydrogen.
- R 3 is alkyl, , more preferably methyl, substituted alkyl, aryl, more preferably phenyl, substituted aryl, preferably substituted phenyl, more preferably 4-substituted phenyl, still more preferably 4- fluorophenyl, or aralkyl.
- R 1 and R 2 are each independently hydrogen, alkyl, substituted alkyl, or aralkyl. More preferably R 2 is alkyl, still more preferably propyl, and R 1 is aralkyl, more preferably benzyl.
- the invention provides a compound represented by Formula (Ib): wherein R 1 , R 2 , R 3 and R 4 are as described above; or a pharmaceutically acceptable salt thereof.
- R 4 is hydrogen, alkyl or substituted alkyl.
- R 3 is alkyl, substituted alkyl, aryl, more preferably phenyl, substituted aryl, preferably substituted phenyl, more preferably 4- substituted phenyl, still more preferably 4-fluorophenyl, or aralkyl.
- R 1 and R 2 are each independently hydrogen, alkyl, substituted alkyl, or aralkyl. More preferably, R 1 is alkyl, still more preferably propyl, and R 2 is aralkyl, more preferably benzyl.
- Another aspect of this invention provides compounds of Formula (II) :
- R 5 and R 6 are each independently hydrogen, alkyl, substituted alkyl, aralkyl, substituted aralkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, or substituted aryl;
- R 7 is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, or substituted aralkyl;
- R 8 is alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl, or substituted aryl; or a pharmaceutically acceptable salt thereof.
- alkyl refers to monovalent straight, branched or cyclic paraffinic hydrocarbon groups that may be derived from an alkane by dropping one hydrogen from the formula.
- Alkyl groups preferably have from 1 to 20 carbon atoms (3 to 20 carbon atoms for cycloalkyls), more preferably 1 to 10 carbon atoms (“lower alkyl”) (3 to 10 carbon atoms for lower cycloalkyls) and most preferably 1 to 6 carbon atoms (3 to 6 carbon atoms for cycloalkyls).
- alkylene and “lower alkylene” refer to divalent radicals of the corresponding alkane.
- substituted alkyl refers to an alkyl group, having from 1 to 5 substituents, and preferably 1 to 3 substituents.
- Preferred substituents include phenyl, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, acyl, acylamino, acyloxy, amino, aralkyl, substituted aralkyl, aryl, substituted aryl, carboxyl, carboxyalkyl, cyano, halogen, hydroxyl, aryloxy, substituted aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, hydroxylamino, alkoxyamino, nitro, alkylthio, substituted alkylthio, arylthio, substituted ary
- alkoxy refers to the group “alkyl-O-", where alkyl is as defined above. Preferred alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.
- alkenyl refers to unsaturated aliphatic hydrocarbon groups having one or more double bonds, preferably having from 2 to 10 carbon atoms, and more preferably 2 to 6 carbon atoms. This term is exemplified by such groups as ethenyl, n-propenyl, iso-propenyl, and the like.
- alkynyl refers to alkynyl groups preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkynyl unsaturation.
- aryl refers to aromatic moieties having from 5 to 14 atoms in the aromatic ring system.
- An aryl group can be carbocyclic (e.g., phenyl, naphthyl) or heterocyclic (a heteroaryl group) having from 1 to 6 heteroatoms (selected from N, S, and O) in the aromatic ring system.
- aryl groups include phenyl, naphthyl, pyridyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, quinolyl, quinazolyl, indolyl, thiazolyl, oxazolyl, and tetrazolyl.
- a preferred aryl group is a phenyl group.
- Aryl groups can be substituted with from 1 to 10 substituents (depending on the number of atoms in the aromatic ring(s)) selected from the group consisting of hydroxy, acyl, alkyl, alkoxy, alkenyl, alkynyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, amino, substituted amino, acyloxy, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, and trihalomethyl.
- Preferred substituents include alkyl, alkoxy, halo, cyano, and trihalomethyl.
- Phenyl groups can optionally be substituted with from 1 to 5 substituents and preferably 1 to 3 substituents.
- aralkyl refers to an alkyl group (preferably a lower alkyl group) substituted with an aryl group as defined herein.
- a "substituted aralkyl” group is an aralkyl in which one or more hydrogen atoms in either the alkyl or the aryl portion of the aralkyl moiety has (have) been substituted by one of the substituents described above for alkyls and aryls, respectively.
- Preferred aralkyl groups include benzyl, 4-fluorobenzyl, 2-pyridinylmethyl, phenethyl, and the like.
- halo or halogen refer to fluoro, chloro, bromo and iodo and preferably is either fluoro or chloro.
- the compounds of the invention can be named according to several naming conventions, e.g., as purine or xanthine derivatives or as azaindene derivatives.
- compound 1 herein can be named as "l-Benzyl-7-phenyI-3-propyl-lH,6H- pyrrolo ⁇ j ⁇ purine ⁇ -dione", "l-Benzyl-7-phenyl-3-propyl-l ⁇ -pyrrolo[l,2-fjpurine- 2,4(3H,6H)-dione " or as "7-Ben2yl-2-phenyl-5-propyl-lH,7H-3a,5,7,8-tetraaza- cyclopenta[a]indene-4,6-dione"; these names are equivalent.
- One of ordinary skill in the art will be able to determine the corresponding structure for any compound named herein.
- “Pharmaceutically acceptable salts” refers to salts of a compound, which can be derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like.
- salts of organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and the like, can be used as the pharmaceutically acceptable salt.
- This invention also encompasses pharmaceutical compositions that are known to those of skill in the art, in which the compounds of this invention, or their pharmaceutically acceptable salts, are used as the active ingredient.
- an “modulator” is any ligand that binds to receptors and thereby alters the proportion of them that are in an active form, resulting in a biological response.
- An “antagonist” is a ligand that binds to or otherwise blocks a receptor and prevents activation of the receptor.
- This invention also encompasses compounds of Formula (I) and Formula (II) which are labeled with radioactive isotopes, such as, but not limited to tritium ( 3 H), carbon ( 14 C), iodine ( 125 I), phosphorus ( 31 P, 32 P, 33 P), and sulfur ( 35 S).
- radioactive isotopes such as, but not limited to tritium ( 3 H), carbon ( 14 C), iodine ( 125 I), phosphorus ( 31 P, 32 P, 33 P), and sulfur ( 35 S).
- the compounds may also be labeled in other ways, e.g., fluorescently or with PET (Positron Emission Tomography) or SPECT (Single Photon Emission Tomography) labels.
- the 3 -position of Formula (I) or the 4-position of Formula (II) may be labeled with tritium.
- the groups at the R 1 or R 2 or R 3 positions of Formula (I), or at the R 4 or R 5 or R 7 positions of Formula (II) may also be labeled with radioactive isotopes such as tritium or carbon isotopes (e.g., 3 H or 14 C).
- stable isotopes such as deuterium ( 2 H) and 13 C that are detected by magnetic resonance imaging or mass spectrometry.
- the compounds of this invention may also be labeled or derivatized, for example, for kinetic binding experiments, for further elucidating metabolic pathways and enzymatic mechanisms, or for characterization by methods known in the art of analytical chemistry.
- the term “labeled” includes the use of any of the isotopically substituted forms herein described.
- the term “therapeutically effective amount” is an amount of an active compound at which a desired pharmacological effect is obtained when administered to a patient.
- the compounds of the invention may be suitably administered to a subject such as a mammal (including a cat dog, monkey, horse, cow, sheep, or (most preferably) a human, alone or as part of a pharmaceutical composition, comprising the compound together with one or more acceptable carriers or excipients and optionally other active or inactive ingredients.
- a mammal including a cat dog, monkey, horse, cow, sheep, or (most preferably) a human
- the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the invention provides pharmaceutical compositions comprising a compound or compounds of the invention, e.g., compounds of Formula (I) or Formula (II).
- compositions of the invention include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
- the compound of the invention is administered transdermally (e.g., using a transdermal patch or iontophoretic techniques).
- Such formulations may conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA (17th ed. 1985).
- Such preparative methods include the step of bringing into association with the molecule to be administered ingredients such as the carrier which constitutes one or more accessory ingredients.
- ingredients such as the carrier which constitutes one or more accessory ingredients.
- the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers or both, and then if necessary shaping the product.
- compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, or packed in liposomes and as a bolus, etc.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets optionally may be coated or scored and may be fo ⁇ nulated so as to provide slow or controlled release of the active ingredient therein.
- dosage forms can be formulated to provide slow or controlled release of the active ingredient.
- dosage forms include, but are not limited to, capsules, granulations and gel-caps.
- compositions suitable for topical administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; and pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia.
- compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
- a compound of the invention is provided in an orally-administered extended-release dosage form.
- the compound is capable of crossing the blood-brain barrier in therapeutically-effective amounts, i.e., the compound can readily penetrate into the central nervous system.
- Application of the subject therapeutics may be local, so as to be administered at the site of interest.
- Various techniques can be used for providing the subject compositions at the site of interest, such as injection, use of catheters, trocars, projectiles, pluronic gel, stents, sustained drug release polymers or other device which provides for internal access.
- the present invention further relates to pharmaceutical compositions as described above for use as a medicament.
- the present invention further relates to use of pharmaceutical compositions as described herein above for the preparation of a medicament for the treatment of condition that is mediated by the A3 receptor, preferably, cancer, cerebral ischemia, inflammation, ischemic heart pre-conditioning and asthma.
- the present invention also relates to a compound of Formula (I) or Formula (II) for use as a medicament; to the use of a compound of Formula (I) or Formula (II) for the preparation of a pharmaceutical composition for the treatment of condition that is mediated by the A 3 receptor, and to a pharmaceutical composition for use in conditions that is mediated by the A 3 receptor, comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier therefore.
- the invention provides methods for making compounds of the invention, e.g., compounds of Formula (I) or Formula (II).
- the compounds of the invention can be made by a variety of methods, some of which are described herein.
- certain 5,6-diamino-lH-pyrimidine-2,4-diones can be prepared as outlined in Scheme 1, and may then be used as precursors for the synthesis of certain compounds of the present invention as exemplified by Schemes 2,3 and 4.
- this synthesis begins with preparation of a 1 -substituted 6-amino-uracil (Scheme 1), which, after protection of the 6-amino group, is N-alkylated and deprotected. Treatment with sodium nitrite followed by reduction provides the 5,6-diamino-uracil, which can then be used in further synthetic steps to obtain compounds of Formula (I) and Formula (II) (Schemes 2, 3 and 4).
- R CH 3
- R CH 3
- a Reagents (i) NH 2 NH 2 , 10% C/Pd, CH 3 OH; (ii) ⁇ -halo-ketone, K 2 CO 3 , DMF, rt, 4-6 h; (iii) CH3COOH, reflux, 4h.
- the present invention also encompasses the use of the disclosed compounds in screening assays to determine the effectiveness of other compounds for binding to the A 3 adenosine receptor through competitive inhibition as determined by various binding assays.
- a screening assay can make use of a labeled form of one of the compounds, preferably tritiated.
- Such screening assays are described in Jacobson and Van Rhee, Purinergic approaches to experimental therapy, Jacobson and Jarvis, ed., Wiley, New York, 1997, pp. 101-128; Mathot et al., Brit. J. Pharmacol., 116: 1957-1964 (1995); van der Wenden et al., J. Med. Chem., 38: 4000-4006 (1995); and van Calenbergh, J. Med. Chem., 40:3765-3772 (1997), the contents of which are hereby incorporated by reference.
- the compounds of the invention are adenosine antagonists possessing A 3 receptor affinity in the low nanomolar range, e.g., having a Ki (hA 3 ) value from binding assay of less than 100 nM, more preferably less than 10 nM, more preferably less than 5 nM, and still more preferably less than 1.0 nM.
- Ki (hA 3 ) value from binding assay of less than 100 nM, more preferably less than 10 nM, more preferably less than 5 nM, and still more preferably less than 1.0 nM.
- 1 -benzyl-7-methyl-3 -propyl- 1 H-imidazo[ 1 ,2-fJpurine-2,4(3H,8H)-dione shows a K; (hA 3 ) value from binding assay of about 0.8 nM.
- a compound of the invention exhibits practically complete selectivity versus the other adenosine receptor subtypes, e.g., having selectivity ratios of Ki (hA0/Ki (hA 3 ) of about 3163, K 1 (hA 2A )/Ki (hA 3 ) of about 6250, IC 5 o(hA 2B )/Ki (hA 3 ) of about 2570.
- the compounds provided by this invention are potent modulators of the A 3 adenosine receptor.
- the A 3 adenosine receptor is thought to mediate many processes, such as inflammation, and mast cell degranulation.
- the A 3 receptor is believed to also play a role in the central nervous system. Mediation of the A 3 receptor seems to induce behavioral depression and protect against cerebral ischemia. Further, mediation of the A 3 adenosine receptor is also thought to induce apoptosis in HL-60 human leukemia cells.
- methods for the treatment of diseases that are mediated by the A 3 receptor are encompassed by this invention.
- the compounds of this invention can also be used as therapeutic agents in regulating cell growth, inducing apoptosis, and controlling the abnormal growth of certain tumors expressing the A 3 adenosine receptor.
- Use of these compounds in methods to treat cancer is also encompassed. This includes cancers that express elevated levels OfA 3 receptors. These cancers would include, but not be limited to, solid tumors, including ovarian cancer, breast cancer, colon cancer, lung cancer, pancreatic cancer and melanoma.
- the compounds and/or pharmaceutical compositions of the invention are administered to a subject in amounts effective to treat or prevent a condition (e.g., cancer).
- a compound of the invention is administered at a dosage of between 0.01 and 100 mg/kg/day, more preferably less than about 10 mg/kg/day, more preferably less than about 50 mg/kg/day, more preferably less than about 1 mg/kg/day, more preferably less than about 0.5 mg/kg/day, and more preferably less than about 0.1 mg/kg/day.
- the compound of the invention is administered at a dosage of at least 0.01 mg/kg/day, about 0.05 mg/kg/day, about 0.1 mg/kg/day, about 0.5 mg/kg/day, about 1.0 mg/kg/day, or about 10 mg/kg/day.
- Two or more compounds and/or pharmaceutical compositions of the invention can also be administered simultaneously or sequentially to a subject administered to a subject to achieve a therapeutic effect. Further, the compounds and/or pharmaceutical compositions of the invention can be administered together with other active ingredients.
- Cells were split 2 or 3 times weekly at a ratio between 1:5 and 1 :20.
- For membrane preparation the culture medium was removed and the cells were washed with PBS and scraped off T75 flasks in ice-cold hypotonic buffer (5 mM Tris HCl, 2 mM EDTA, pH 7.4).
- the cell suspension was homogenized with Polytron and the homogenate was spun for 10 min at 1,000 x g. The supernatant was then centrifuged for 30 min at 100,000 x g.
- the membrane pellet was resuspended in 50 mM Tris HCl buffer pH 7.4 (for A 3 adenosine receptors: 50 mM Tris HCl, 10 mM MgC12, 1 mM EDTA) and incubated with 3 UI/mL of Adenosine deaminase for 30 min at 37°C. Then the suspension was frozen at -8O 0 C.
- HEK 293 cells transfected with the human recombinant A2B adenosine receptor were obtained from Receptor Biology, Inc. (Beltsville, MD, USA).
- Binding of [ 3 H]-DPCPX to CHO cells transfected with the human recombinant Aj adenosine receptor was performed according to the method described by Klotz et al., J. Biol. Chem., 260, 14659-14664, (1985). Displacement experiments were performed for 120 min at 25°C in 0.2 mL of 50 mM Tris HCl buffer pH 7.4 containing 1 nM [ 3 H]-DPCPX, diluted membranes (50 ⁇ g of protein/assay) and at least 6-8 different concentrations of antagonists studied. Non-specific binding was determined in the presence of 10 ⁇ M of CHA and this was always ⁇ 10% of the total binding.
- Binding of [ 3 H]-SCH 58261 to CHO cells transfected with the human recombinant A 2A adenosine receptors was performed using 0.2 mL 50 mM Tris HCl buffer, 10 mM MgCl 2 pH 7.4 and at least 6-8 different concentrations of antagonists studied for an incubation time of 30 min at 25°C. Non-specific binding was determined in the presence of 50 ⁇ M NECA and was about 20% of total binding.
- Binding of [ 3 H]-MRE 3008F20 to CHO cells transfected with the human recombinant A 3 adenosine receptors was performed according to Varani et al., 2000. Competition experiments were carried out in duplicate in a final volume of 100 ⁇ l in test tubes containing 1 nM [ 3 H]-MRE 3008F20, 50 mM Tris HCl buffer, 10 mM MgCl 2 , 1 mM EDTA pH 7.4 and 100 ⁇ l of diluted membranes (50 ⁇ g of protein/assay) and at least 8-10 different concentrations of examined antagonists. Incubation time was 120 min at 4°C, according to the results of previous time-course experiments. Non-specific binding was defined as binding in the presence of 1 ⁇ M MRE 3008F20 and was about 30% of total binding.
- Reaction progress and product mixtures were monitored by thin-layer chromatography (TLC) on silica gel (procoated F 254 Merck plates) and visualized with aqueous potassium permanganate or a methanolic solution of ninhydrin.
- H-NMR were determined in CDCl 3 or OMSO-d ⁇ solutions with a Bruker AC 200 spectrometer; peak positions are given in parts per million ( ⁇ ) downfield from tetramethylsilane as internal standard and J values are given in Hertz.
- Light petroleum refers to the fractions boiling at 40-60 0 C. Melting points were determined on a Buchi-Tottoli instrument and are uncorrected. Chromatography was performed on Merck 230-400 mesh silica gel. Organic solutions were dried over anhydrous sodium sulfate.
- the compounds of this invention show good affinity at the A 3 receptor, and good selectivity versus the A 1 receptor.
- Results of radioligand binding assays displacing agonists with representative preferred compounds at human Ai, A 2A , A 2B , and A 3 adenosine receptors expressed in CHO cells are shown in Table 2.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06734138A EP1845993A4 (en) | 2005-02-02 | 2006-02-01 | Novel adenosine a3 receptor modulators |
AU2006210817A AU2006210817B2 (en) | 2005-02-02 | 2006-02-01 | Novel adenosine A3 receptor modulators |
JP2007554173A JP2008538099A (en) | 2005-02-02 | 2006-02-01 | Novel adenosine A3 receptor modulator |
CA002596612A CA2596612A1 (en) | 2005-02-02 | 2006-02-01 | Novel adenosine a3 receptor modulators |
MX2007008501A MX2007008501A (en) | 2005-02-02 | 2006-02-01 | Novel adenosine a3 receptor modulators. |
BRPI0606750-6A BRPI0606750A2 (en) | 2005-02-02 | 2006-02-01 | compound or a pharmaceutically acceptable salt thereof, and, pharmaceutical composition |
NZ556649A NZ556649A (en) | 2005-02-02 | 2006-02-01 | Novel adenosine A3 receptor modulators |
IL184532A IL184532A0 (en) | 2005-02-02 | 2007-07-10 | Novel adenosine a3 receptor modulators |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64972605P | 2005-02-02 | 2005-02-02 | |
US60/649,726 | 2005-02-02 | ||
US11/344,295 US7435740B2 (en) | 2005-02-02 | 2006-01-31 | Adenosine A3 receptor modulators |
US11/344,295 | 2006-01-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006083916A2 true WO2006083916A2 (en) | 2006-08-10 |
WO2006083916A3 WO2006083916A3 (en) | 2007-12-21 |
Family
ID=36777854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/003477 WO2006083916A2 (en) | 2005-02-02 | 2006-02-01 | Novel adenosine a3 receptor modulators |
Country Status (11)
Country | Link |
---|---|
US (1) | US7435740B2 (en) |
EP (1) | EP1845993A4 (en) |
JP (1) | JP2008538099A (en) |
KR (1) | KR20070100331A (en) |
AU (1) | AU2006210817B2 (en) |
BR (1) | BRPI0606750A2 (en) |
CA (1) | CA2596612A1 (en) |
IL (1) | IL184532A0 (en) |
MX (1) | MX2007008501A (en) |
NZ (1) | NZ556649A (en) |
WO (1) | WO2006083916A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009092602A2 (en) * | 2008-01-24 | 2009-07-30 | Universität Zürich | Anti-angiogenic compounds |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
JP2011528363A (en) * | 2008-07-16 | 2011-11-17 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | Treatment of atherosclerosis |
WO2011010306A1 (en) | 2009-07-21 | 2011-01-27 | Ramot At Tel-Aviv University Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
-
2006
- 2006-01-31 US US11/344,295 patent/US7435740B2/en not_active Expired - Fee Related
- 2006-02-01 CA CA002596612A patent/CA2596612A1/en not_active Abandoned
- 2006-02-01 NZ NZ556649A patent/NZ556649A/en not_active IP Right Cessation
- 2006-02-01 WO PCT/US2006/003477 patent/WO2006083916A2/en active Application Filing
- 2006-02-01 EP EP06734138A patent/EP1845993A4/en not_active Withdrawn
- 2006-02-01 JP JP2007554173A patent/JP2008538099A/en not_active Withdrawn
- 2006-02-01 KR KR1020077017126A patent/KR20070100331A/en not_active Application Discontinuation
- 2006-02-01 BR BRPI0606750-6A patent/BRPI0606750A2/en not_active IP Right Cessation
- 2006-02-01 MX MX2007008501A patent/MX2007008501A/en active IP Right Grant
- 2006-02-01 AU AU2006210817A patent/AU2006210817B2/en not_active Ceased
-
2007
- 2007-07-10 IL IL184532A patent/IL184532A0/en unknown
Non-Patent Citations (12)
Title |
---|
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY |
BARALDI ET AL., DRUG DEVELOPMENT RESEARCH, vol. 58, 2003, pages 315 - 329 |
BARALDI ET AL., SYNTHESIS, vol. 5, 2001, pages 773 - 777 |
DRABCZYNSKA ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, 2004, pages 4895 - 4908 |
DRABCZYNSKA ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, 2003, pages 397 - 402 |
JACOBSON; VAN RHEE: "Purinergic approaches to experimental therapy", 1997, WILEY, pages: 101 - 128 |
KLOTZ ET AL., NAUNYN SCHMIED. ARCH. PHARMACOL., vol. 357, 1998, pages 1 - 9 |
MATHOT ET AL., BRIT. J. PHARMACOL., vol. 116, 1995, pages 1957 - 1964 |
PRIEGO ET AL., J. MED. CHEM., vol. 45, 2002, pages 3337 - 3344 |
See also references of EP1845993A4 |
VAN CALENBERGH, J. MED. CHEM., vol. 40, 1997, pages 3765 - 3772 |
VAN DER WENDEN ET AL., J. MED. CHEM., vol. 38, 1995, pages 4000 - 4006 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009092602A2 (en) * | 2008-01-24 | 2009-07-30 | Universität Zürich | Anti-angiogenic compounds |
WO2009092602A3 (en) * | 2008-01-24 | 2009-11-05 | Universität Zürich | Anti-angiogenic compounds |
US8765775B2 (en) | 2008-01-24 | 2014-07-01 | Universitaet Zuerich | Anti-angiogenic compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1845993A4 (en) | 2009-03-11 |
KR20070100331A (en) | 2007-10-10 |
US20060178385A1 (en) | 2006-08-10 |
US7435740B2 (en) | 2008-10-14 |
JP2008538099A (en) | 2008-10-09 |
EP1845993A2 (en) | 2007-10-24 |
AU2006210817A2 (en) | 2006-08-10 |
IL184532A0 (en) | 2007-10-31 |
AU2006210817B2 (en) | 2010-12-23 |
NZ556649A (en) | 2010-03-26 |
CA2596612A1 (en) | 2006-08-10 |
MX2007008501A (en) | 2007-09-14 |
BRPI0606750A2 (en) | 2009-07-14 |
WO2006083916A3 (en) | 2007-12-21 |
AU2006210817A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6776378B2 (en) | 4,6-Diaminoquinazolines as Cot modulators and how to use them | |
KR101227738B1 (en) | Organic compounds | |
JP6437519B2 (en) | Organic compounds | |
US8722877B2 (en) | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | |
JP5084725B2 (en) | Organic compounds | |
TW200846001A (en) | Therapeutic compounds | |
KR20100094551A (en) | Organic compounds | |
JP5728499B2 (en) | Compounds and compositions as protein kinase inhibitors | |
US20030004180A1 (en) | Pyrazolo-pyridine derivatives as ligands for gaba receptors | |
JP7406691B2 (en) | Crystal forms and salt types of triazolopyrimidine compounds and their preparation methods | |
JP2020528922A (en) | Thiazolopyridine derivative as an adenosine receptor antagonist | |
EP1845993A2 (en) | Novel adenosine a3 receptor modulators | |
JP2022524914A (en) | Thiazolopyridine derivative as an adenosine receptor antagonist | |
CN116425756A (en) | Adenosine receptor antagonist compounds and uses thereof | |
MXPA04000492A (en) | Chemical compounds. | |
CN114276349B (en) | 2-aminopterine derivatives or salts thereof, and preparation method and application thereof | |
JPH06234770A (en) | 2-thienylimidazo(2,1-b)-benzothiazole-3-acetic acid derivatives, their production and their application to medical treatment | |
NZ622594B2 (en) | Pyrazoloquinoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680003937.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 978/MUMNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 184532 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/008501 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 556649 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077017126 Country of ref document: KR Ref document number: 1020077017123 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2596612 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007554173 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006210817 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006734138 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006210817 Country of ref document: AU Date of ref document: 20060201 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0606750 Country of ref document: BR Kind code of ref document: A2 |